Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Recent advances in immunosuppressive therapy for prevention of renal allograft rejection.

Publication ,  Journal Article
Lunsford, KE; Barbas, AS; Brennan, TV
Published in: Curr Opin Organ Transplant
August 2011

PURPOSE OF REVIEW: Current immunosuppressive therapies are highly successful at regulating acute allograft rejection and inducing long-term transplanted kidney survival; however, currently available medications are associated with generalized immune suppression and drug toxicities, including nephrotoxicity. In recent years, advances in immunosuppression that target specific pathways involved in immune activation have been developed. RECENT FINDINGS: In particular, promising medications are currently under evaluation that target ischemia-reperfusion injury as well as the cellular and humoral branches of the adaptive immune response. Targets of T-cell-mediated activation include antibodies and fusion proteins interfering with LFA-1/ICAM-1, CD2/LFA-3, CD40/CD154, and CD28/B7.1 and B7.2 interactions. Intracellular targets involved in T- and B-cell activation pathways are being evaluated, including protein kinase C inhibitors, Janus-associated kinase (JAK) inhibitors, and proteasome inhibitors. Several new medications demonstrate promise in inhibiting donor-directed humoral immunity by targeting B-cell-activating factor (BAFF) and complement activation pathways. SUMMARY: The present review evaluates the recent clinical advances in immunosuppressive therapies for kidney transplantation. Publications regarding advances in immunosuppressive therapies over the past year were evaluated in the context of the specific immune pathways involved in allograft rejection.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Opin Organ Transplant

DOI

EISSN

1531-7013

Publication Date

August 2011

Volume

16

Issue

4

Start / End Page

390 / 397

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Homologous
  • Transplantation Tolerance
  • Time Factors
  • T-Lymphocytes
  • Surgery
  • Signal Transduction
  • Reperfusion Injury
  • Kidney Transplantation
  • Immunosuppressive Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lunsford, K. E., Barbas, A. S., & Brennan, T. V. (2011). Recent advances in immunosuppressive therapy for prevention of renal allograft rejection. Curr Opin Organ Transplant, 16(4), 390–397. https://doi.org/10.1097/MOT.0b013e328348b420
Lunsford, Keri E., Andrew S. Barbas, and Todd V. Brennan. “Recent advances in immunosuppressive therapy for prevention of renal allograft rejection.Curr Opin Organ Transplant 16, no. 4 (August 2011): 390–97. https://doi.org/10.1097/MOT.0b013e328348b420.
Lunsford KE, Barbas AS, Brennan TV. Recent advances in immunosuppressive therapy for prevention of renal allograft rejection. Curr Opin Organ Transplant. 2011 Aug;16(4):390–7.
Lunsford, Keri E., et al. “Recent advances in immunosuppressive therapy for prevention of renal allograft rejection.Curr Opin Organ Transplant, vol. 16, no. 4, Aug. 2011, pp. 390–97. Pubmed, doi:10.1097/MOT.0b013e328348b420.
Lunsford KE, Barbas AS, Brennan TV. Recent advances in immunosuppressive therapy for prevention of renal allograft rejection. Curr Opin Organ Transplant. 2011 Aug;16(4):390–397.

Published In

Curr Opin Organ Transplant

DOI

EISSN

1531-7013

Publication Date

August 2011

Volume

16

Issue

4

Start / End Page

390 / 397

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Homologous
  • Transplantation Tolerance
  • Time Factors
  • T-Lymphocytes
  • Surgery
  • Signal Transduction
  • Reperfusion Injury
  • Kidney Transplantation
  • Immunosuppressive Agents